Search results for: 'c2 from composit'

05 Feb 2021  |  North America  |  Market Research

Shifting Spotlight from Product- to Value-based Outcomes Intensifies Growth in the US Real-world Evidence IT Solutions Market

Early-stage R&D and Commercial Applications Fuel the Growth Pipeline

Infographics

×

The US healthcare industrys transition to a patient-centric model is moving rapidly with focus on outcomes and value; however, drug prices have increased and pharmaceutical research and development (R&D) productivity is at its lowest. The healthcare industry and IT solutions providers are finding real-world evidence (RWE) as a potential solution to...

This study analyzes the emergence of engineered antibody therapeutics for cancer, examining the factors driving their adoption. The limitations of monoclonal antibodies have led to an increasing demand for novel formats. Companies are developing multispecific antibodies, such as bispecifics and trispecifics, and antibody fragments, such as Fab and ...

The African continent grapples with a huge burden of communicable diseases, particularly HIV/AIDS, tuberculosis, and malaria. With African governments facing major health financing challenges, a significant proportion of these disease areas are financed by global aid organizations that are also helping in poverty eradication in the continent. Paral...

24 Aug 2021  |  North America  |  Market Research

US and EU Biotech Industry VC Investment Growth Opportunities

Future Growth Potential Driven by Next-generation Cell and Gene Platform Technology Powered by AI

Infographics

×

With this research service, Frost & Sullivan provides critical insights into the biotech, and cell and gene therapy (CGT) venture capital (VC) investment trends highlighting the growth opportunities, key countries in the VC environment, and major trends in cell and gene therapy segment. The study also identifies actionable growth opportunities for ...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules, and the rate of return has shrunk from 16% in 2011 to almost 11% in 2018. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16Percentage in 2011 to almost 11Percentage in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniqu...

This study explores the global immuno-oncology (I-O) markets evolution from 2020 to 2025. An extensive analysis is provided on the growth opportunities envisioned by Frost & Sullivan to help stakeholders leverage their momentum and disrupt the market by offering best-in-class solutions. The study considers oncology agents for which the immune syst...

15 Oct 2024  |  Global  |  Technology Research

Emerging Non-opioid Treatments for Pain Management

Advances in Non-opioid Therapies for Neuropathic, Migraine, and Cancer Pain Management Unlock New Growth Opportunities

Infographics

×

The analysis explores cutting-edge advancements in non-opioid medications by delving into their mechanisms of action at a molecular scale, scrutinizing results from current clinical research initiatives, and appraising preparedness for and plausibility of regulatory approval. The considerations aim to highlight how these treatments may offer viable...

Overall Impact of Breakthrough Innovations in Gut Microbial Health Covered in this Research - Microbiome expertise: Meeting translational research needs from medical, academic and industrial communities through deep diving know-how and expertise across multiple scientific platforms - Nutrition and therapeutic fields: Enabling precision medicine an...